On November 26, Glonghui reported that the usa biopharmaceutical company alector (ALEC.US) dropped over 33.5% in pre-market trading, reaching $2.63. In terms of news, alector stated that its experimental drug did not meet the primary endpoint of slowing the progression of Alzheimer's disease in a mid-stage trial and that it would cease the long-term expansion study of the drug. Additionally, the company plans to lay off 17% of its workforce, affecting 244 employees, by December 31, 2023. Current cash and cash equivalents should be sufficient to support the company's operation until 2026. (Glonghui)
美股异动｜Alector盘前跌超33.5% 阿尔茨海默氏症药物中期试验未达主要终点
US stock anomaly | Alector fell more than 33.5% before the market, and the mid-term trial of Alzheimer's drug did not reach the main endpoint.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated